Digital Implementation Support to Achieve Uptake and Integration of Task-Shared Care for Schizophrenia in Primary Care in India
Launched by HARVARD MEDICAL SCHOOL (HMS AND HSDM) · Sep 12, 2023
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a digital platform, called mindLAMP, can improve the care and support for individuals with schizophrenia in primary care settings in India. Schizophrenia is a serious mental health condition that can be challenging to manage, especially in low-income areas where access to treatment is limited. The trial aims to see if using mindLAMP alongside a community-based rehabilitation program can help people with schizophrenia recover better and whether it can make it easier for doctors to provide this type of care.
To participate in the trial, individuals must have a primary diagnosis of schizophrenia, have been living with the condition for more than a year, and have at least one health issue that could increase their risk of early death, like high blood pressure or diabetes. Participants should be able to use a smartphone and must be willing to stay in the study area for the duration of the trial. However, those with major visual impairments, cognitive issues, or who don’t speak Hindi or Kannada will not be eligible. Participants can expect to receive support through the digital platform and will be part of a program aimed at improving their overall health and quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary diagnosis of schizophrenia per IDC-10 diagnostic criteria for research and an illness duration of greater than 12 months and overall moderate level of severity on the CGI-SCH scale
- • At least one risk factor for early mortality (e.g. hypertension, diabetes, dyslipidemia, etc)
- • Willingness to stay in the study area during the trial period
- • Ability to operate a smartphone
- Exclusion Criteria:
- • Major visual impairment or inability to operate a smartphone
- • Cognitive impairment or diagnosis of dementia
- • Planning to move out of the study area in the next 12 months
- • Does not speak Hindi or Kannada
About Harvard Medical School (Hms And Hsdm)
Harvard Medical School (HMS) and Harvard School of Dental Medicine (HSDM) are prestigious institutions renowned for their commitment to advancing medical and dental research, education, and patient care. As clinical trial sponsors, HMS and HSDM leverage their robust academic resources, cutting-edge laboratories, and a collaborative network of healthcare professionals to conduct innovative research that addresses critical health challenges. With a focus on translating scientific discoveries into clinical applications, these institutions foster an environment that promotes ethical research practices and prioritizes participant safety, ensuring that their clinical trials contribute significantly to the field of medicine and the well-being of communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
John A Naslund, PhD
Principal Investigator
Harvard Medical School (HMS and HSDM)
John Torous, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Narayana Manjunatha, MD, MBBS
Principal Investigator
National Institute of Mental Health and Neuro Sciences, India
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported